--- title: "Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials" type: "News" locale: "en" url: "https://longbridge.com/en/news/286239732.md" description: "Azitra reported a Q1 2026 net loss of $3.9 million, with cash and equivalents totaling $10.1 million. R&D expenses were $1.6 million, and G&A expenses were $2.4 million. The company expanded its ATR-04 trial sites and received a new U.S. patent for ATR-12, with topline data expected in H2 2026. The first patient has been dosed in the ATR-04 trial, and preclinical progress for ATR-01 is ongoing. A new cosmeceutical initiative has also been launched, with results anticipated in mid-2026." datetime: "2026-05-13T10:13:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286239732.md) - [en](https://longbridge.com/en/news/286239732.md) - [zh-HK](https://longbridge.com/zh-HK/news/286239732.md) --- # Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials Azitra reported a net loss of $3.9 million for the quarter ended March 31, 2026, and held $10.1 million in cash and cash equivalents as of that date. R&D expense was $1.6 million and G&A expense was $2.4 million for the quarter. The company highlighted clinical and platform progress including expansion of ATR-04 trial sites and a new U.S. patent for ATR-12. **Financial Highlights** - Net loss: $3.9 million for the quarter ended March 31, 2026 (compared to $3.1 million in the comparable period of 2025). - Research and development expense: $1.6 million for the quarter ended March 31, 2026 (compared to $1.25 million in Q1 2025). - General and administrative expense: $2.4 million for the quarter ended March 31, 2026 (compared to $1.85 million in Q1 2025). - Cash and cash equivalents: $10.1 million as of March 31, 2026. - Loss per share, basic and diluted: $(0.25) for the quarter ended March 31, 2026 (vs. $(1.55) in the comparable period of 2025). **Business Highlights** - Clinical expansion: Added MD Anderson Cancer Center as a clinical site for the Phase 1/2 ATR-04 trial targeting EGFR inhibitor–associated rash to enhance patient access and trial execution. - Product development milestones: ATR-12 (lead candidate for Netherton syndrome) received a new U.S. patent and is being evaluated in a Phase 1b trial with topline data anticipated in H2 2026. - Advancement of ATR-04: First patient dosed in the Phase 1/2 ATR-04 trial; topline data from the first cohort expected in H2 2026. - Preclinical progress: ATR-01 showed positive preclinical data demonstrating delivery of functional filaggrin and repair of damaged model skin; IND-enabling studies continue in 2026. - New cosmeceutical initiative: Launched programs leveraging proprietary filaggrin protein and peptide technologies for cosmetic and consumer markets, with repeat-application explanted skin results due mid-2026 and a planned human cosmetic application study in Q3 2026. Original SEC Filing: Azitra, Inc. \[ AZTR \] - 8-K - May. 12, 2026 **Disclaimer** This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. ### Related Stocks - [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research - [Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News](https://longbridge.com/en/news/286262344.md) - [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md) - [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md) - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)